x
ServiziMenu principaleHome
Print
Home > Pubblicazioni > Pubblicazioni > 2011-2019

Pubblicazioni dal 2011 al 2019

  • Tibaldi C, Camerini A, Tiseo M, Mazzoni F, Barbieri F, Vittimberga I, Brighenti M, Boni L, Baldini E, Gilli A, Honeywell R, Chartoire M, Peters GJ, Giovannetti E; Italian Oncological Group of Clinical Research (GOIRC).
    Cytidine deaminase enzymatic activity is a prognostic biomarker in gemcitabine/platinum-treated advanced non-small-cell lung cancer: a prospective validation study.
    Br J Cancer. 2018 Nov 8. doi: 10.1038/s41416-018-0307-3
  • Viale G, de Snoo FA, Slaets L, Bogaerts J, van 't Veer L, Rutgers EJ, Piccart-Gebhart MJ, Stork-Sloots L, Glas A, Russo L, Dell'Orto P, Tryfonidis K, Litière S, Cardoso F; MINDACT investigators.
    Immunohistochemical versus molecular (BluePrint and MammaPrint) subtyping of breast carcinoma. Outcome results from the EORTC 10041/BIG 3-04 MINDACT trial.
    Breast Cancer Res Treat. 2018 Jan;167(1):123-131
  • Liguigli W, Tomasello G, Toppo L, Poli R, Lazzarelli S, Negri F, Perrucci B, Curti A, Brighenti M, Donati G, Nazzari M, Martinotti M, Vismarra M, Rovatti M, Passalacqua R.
    Safety and efficacy of dose-dense chemotherapy with TCF regimen in elderly patients with locally advanced or metastatic gastric cancer.
    Tumori. 2017 Jan 21;103(1):93-100.
  • Marcello Tiseo, Luca Boni, Francesca Ambrosio, Andrea Camerini, Editta Baldini, Saverio Cinieri, Matteo Brighenti, Francesca Zanelli, Efisio Defraia, Rita Chiari, Claudio Dazzi, Carmelo Tibaldi, Gianni Michele Turolla, Vito D’Alessandro, Nicoletta Zilembo, Anna Rita Trolese, Francesco Grossi, Ferdinando Riccardi, and Andrea Ardizzoni
    Italian, Multicenter, Phase III, Randomized Study of Cisplatin Plus Etoposide With or Without Bevacizumab as First-Line Treatment in Extensive-Disease Small-Cell Lung Cancer: The GOIRC-AIFA FARM6PMFJM Trial
    J Clin Oncol. 2017 Jan 30:JCO2016694844.
  • Gunter von Minckwitz, M.D., Marion Procter, Ph.D., Evandro de Azambuja, M.D., Dimitrios Zardavas, M.D., Mark Benyunes, M.D., Giuseppe Viale, M.D., Thomas Suter, M.D., Amal Arahmani, Ph.D., Nathalie Rouchet, M.Sc., Emma Clark, M.Sc., Adam Knott, Ph.D., Istvan Lang, M.D., Christelle Levy, M.D., Denise A. Yardley, M.D., Jose Bines, M.D., Richard D. Gelber, Ph.D., Martine Piccart, M.D., and Jose Baselga, M.D., for the APHINITY Steering Committee and Investigators*
    Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer
    N Engl J Med 2017; 377:122-131 July 13, 2017
  • Passalacqua R, Lazzarelli S, Donini M, Montironi R, Tambaro R, De Giorgi U, Pignata S, Palumbo R, Ceresoli GL, Del Conte G, Tonini G, Morelli F, Nolè F, Panni S, Rondini E, Guida A, Zucali PA, Doni L, Iezzi E, Caminiti C
    Real-life clinical practice results with vinflunine in patients with relapsed platinum-treated metastatic urothelial carcinoma: an Italian multicenter study (MOVIE-GOIRC 01-2014)
    BMC Cancer, 2017, 17:493
  • Gianluca Tomasello, Nicola Valeri, Michele Ghidini, Elizabeth C. Smyth, Wanda Liguigli, Laura Toppo, Rodolfo Mattioli, Alessandra Curti, Jens C. Hahne, Federica M. Negri, Stefano Panni, Margherita Ratti, Silvia Lazzarelli1, Fabiana Gerevini, Chiara Colombi, Andrea Panni, Massimo Rovatti, Leonardo Treccani, Mario Martinotti and Rodolfo Passalacqua
    First-line dose-dense chemotherapy with docetaxel, cisplatin, folinic acid and 5-fluorouracil (DCF) plus panitumumab in patients with locally advanced or metastatic cancer of the stomach or gastroesophageal junction: final results and biomarker analysis from an italian oncology group for clinical research (GOIRC) phase II study
    Oncotarget, 2017, Vol. 8, (No. 67), pp: 111795-111806
  • Aalders KC, Kuijer A, Straver ME, Slaets L, Litiere S, Viale G, Van't Veer LJ, Glas AM, Delorenzi M, van Dalen T, Tryfonidis K, Piccart MJ, Cardoso F, Rutgers EJ; TRANSBIG Consortium and the MINDACT Investigators.
    Characterisation of multifocal breast cancer using the 70-gene signature in clinical low-risk patients enrolled in the EORTC 10041/BIG 03-04 MINDACT trial.
    Eur J Cancer. 2017 Jul;79:98-105..
  • Emile JF, Julié C, Le Malicot K, Lepage C, Tabernero J, Mini E, Folprecht G, Van Laethem JL, Dimet S, Boulagnon-Rombi C, Allard MA, Penault-Llorca F, Bennouna J, Laurent-Puig P, Taieb J; PETACC8 Study Investigators; Austrian Breast and Colorectal cancer Study Group (ABCSG); Belgian Group of Digestive Oncology (BGDO); Lone Nørgård Petersen; Fédération Francophone de Cancérologie Digestive (FFCD); Fédération Nationale des Centres de Lutte Contre le Cancer (UNICANCER); Fédération Nationale des Centres de Lutte Contre le Cancer Association Européenne de Recherche en Oncologie (AERO); Arbeitsgemeinschaft Internistische Onkologie (AIO); Gruppo Italiano per lo Studio dei Carcinomi dell'Apparato Digerente (GISCAD); Gruppo Oncologico dell'Italia Meridionale (GOIM); Istituto Oncologico Romagnolo (IOR); Gruppo Cooperativo Chirurgico Italiano (GOCCI); Gruppo Oncologico Nord Ovest (GONO); Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC); Gruppo Cooperativo do Cancro Digestivo da Associação Portuguesa de Investigação Oncológica (GCCD, APIO); Grupo Español para el Tratamiento de los Tumores Digestivos (TTD); John Allen Bridgewater
    Prospective validation of a lymphocyte infiltration prognostic test in stage III colon cancer patients treated with adjuvant FOLFOX.
    Eur J Cancer. 2017 Sep;82:16-24.
  • Van Kruijsdijk RC, Visseren FL, Boni L, Groen HJ, Dingemans AM, Aerts JG, van der Graaf Y, Ardizzoni A, Smit EF.
    Pemetrexed plus carboplatin versus pemetrexed in pretreated patients with advanced non-squamous non-small-cell lung cancer: treating the right patients based on individualized treatment effect prediction.
    Ann Oncol. 2016 Jul;27(7):1280-6.
  • Cardoso F, van't Veer LJ, Bogaerts J, Slaets L, Viale G, Delaloge S, Pierga JY, Brain E, Causeret S, DeLorenzi M, Glas AM, Golfinopoulos V, Goulioti T, Knox S, Matos E, Meulemans B, Neijenhuis PA, Nitz U, Passalacqua R, Ravdin P, Rubio IT, Saghatchian M, Smilde TJ, Sotiriou C, Stork L, Straehle C, Thomas G, Thompson AM, van der Hoeven JM, Vuylsteke P, Bernards R, Tryfonidis K, Rutgers E, Piccart M; MINDACT Investigators.
    70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer.
    N Engl J Med. 2016 Aug 25;375(8):717-29
  • Tiseo M, Boni L, Ambrosio F, Camerini A, Vitale MG, Baldini E, Cinieri S, Zanelli F, Defraia E, Passalacqua R, Crino L, Dazzi C, Tibaldi C, Turolla GM, D'Alessandro V, Zilembo N, Riccardi F, Ardizzoni A; Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC).
    Italian multicenter phase III randomized study of cisplatin-etoposide with or without bevacizumab as first-line treatment in extensive stage small cell lung cancer: treatment rationale and protocol design of the GOIRC-AIFA FARM6PMFJM trial.
    Clin Lung Cancer. 2015 Jan;16(1):67-70. (IF=3.104)
  • Donini M, Buti S, Lazzarelli S, Bozzetti R, Rivoltini L, Camisaschi C, Castelli C, Bearz A, Simonelli C, Lo Re G, Mattioli R, Caminiti C, Passalacqua R; GOIRC (Italian Oncology Group for Clinical Research).
    Dose-finding/phase II trial: bevacizumab, immunotherapy, and chemotherapy (BIC) in metastatic renal cell cancer (mRCC). Antitumor effects and variations of circulating T regulatory cells (Treg).
    Target Oncol. 2015 Jun;10(2):277-86. doi: 10.1007/s11523-014-0337-6. Epub 2014 Sep 19. (IF=4.000)
  • Bajetta E, Floriani I, Di Bartolomeo M, Labianca R, Falcone A, Di Costanzo F, Comella G, Amadori D, Pinto C, Carlomagno C, Nitti D, Daniele B, Mini E, Poli D, Santoro A, Mosconi S, Casaretti R, Boni C, Pinotti G, Bidoli P, Landi L, Rosati G, Ravaioli A, Cantore M, Di Fabio F, Aitini E, Marchet A; ITACA-S (Intergroup Trial of Adjuvant Chemotherapy in Adenocarcinoma of the Stomach Trial) Study Group.
    Randomized trial on adjuvant treatment with FOLFIRI followed by docetaxel and cisplatin versus 5-fluorouracil and folinic acid for radically resected gastric cancer.
    Ann Oncol. 2014 Jul;25(7):1373-8
  • Passalacqua R, Caminiti C, Buti S, Porta C, Camisa R, Braglia L, Tomasello G, Vaglio A, Labianca R, Rondini E, Sabbatini R, Nastasi G, Artioli F, Prati A, Potenzoni M, Pezzuolo D, Oliva E, Alberici F, Buzio C; for the POLAR-01 Trial Investigators.
    Adjuvant Low-Dose Interleukin-2 (IL-2) Plus Interferon-a (IFN-a) in Operable Renal Cell Carcinoma (RCC): A Phase III, Randomized, Multicentre Trial of the Italian Oncology Group for Clinical Research (GOIRC).
    J Immunother. November/December;37 (9):440-447, 2014. (IF=4.008)
  • Sergio Bracarda, Camillo Porta, Corrado Boni, Armando Santoro, Claudia Mucciarini, Antonio Pazzola, Enrico Cortesi, Donatello Gasparro, Roberto Labianca, Francesco Di Costanzo, Alfredo Falcone, Michela Cinquini, Claudia Caserta, Chiara Paglino, Verena De Angelis.
    Could Interferon Still Play a Role in Metastatic Renal Cell Carcinoma? A Randomized Study of Two Schedules of Sorafenib Plus Interferon-Alpha 2a (RAPSODY).
    European Urology 63: 254-261, 2013
  • Bisagni G, Musolino A, Panebianco M, De Matteis A, Nuzzo F, Ardizzoni A, Gori S, Gamucci T, Passalacqua R, Gnoni R, Moretti G, Boni C.
    The Breast Avastin Trial: phase II study of bevacizumab maintenance therapy after induction chemotherapy with docetaxel and capecitabine for the first-line treatment of patients with locally recurrent or metastatic breast cancer.
    Cancer Chemother Pharmacol. 2013 Apr;71(4):1051-7
  • Tiseo M, Bordi P, Bortesi B, Boni L, Boni C, Baldini E, Grossi F, Recchia F, Zanelli F, Fontanini G, Naldi N, Campanini N, Azzoni C, Bordi C, Ardizzoni A.
    ERCC1/BRCA1 expression and gene polymorphisms as prognostic and predictive factors in advanced NSCLC treated with or without cisplatin.
    Br J Cancer. 2013 Apr 30;108(8):1695-703
  • Mazzoni F, Cecere FL, Meoni G, Giuliani C, Boni L, Camerini A, Lucchesi S, Martella F, Amoroso D, Lucherini E, Torricelli F, Di Costanzo F.
    Phase II trial of customized first line chemotherapy according to ERCC1 and RRM1 SNPs in patients with advanced non-small-cell lung cancer.
    Lung Cancer. Nov; 82(2): 288-93, 2013. (IF=3.392)
  • Boni C, Tiseo M, Boni L, Baldini E, Recchia F, Barone C, Grossi F, Germano D, Matano E, Marini G, Labianca R, Di Costanzo F, Bagnulo A, Pennucci C, Caroti C, Mencoboni M, Zanelli F, Prochilo T, Cafferata MA, Ardizzoni A; Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC).
    Triplets versus doublets, with or without cisplatin, in the first-line treatment of stage IIIB-IV non-small cell lung cancer (NSCLC) patients: a multicenter randomised factorial trial (FAST).
    Br J Cancer 106 (4): 658-65, 2012
  • Marcello Tiseo, Elisa Giovannetti, Carmelo Tibaldi, Andrea Camerini, Francesco Di Costanzo, Fausto Barbieri, Jacobus A. Burgers, Andrew Vincent, Godefridus J. Peters, Egbert F. Smit, Andrea Ardizzoni.
    Pharmacogenetic study of patients with advanced non-small cell lung cancer (NSCLC) treated with second-line pemetrexed or pemetrexed–carboplatin.
    Lung Cancer 78: 92– 99, 2012
  • Andrea Ardizzoni, Marcello Tiseo, Luca Boni, Andrew D Vincent, Rodolfo Passalacqua, Sebastiano Buti, Domenico Amoroso, Andrea Camerini, Roberto Labianca, Giovenzio Genestreti, Corrado Boni, Libero Ciuffreda, Francesco Di Costanzo, Filippo de Marinis, Lucio Crino, Antonio Santo, Andrea Pazzola, Fausto Barbieri, Nicoletta Zilembo, Ida Colantonio, Carmelo Tibaldi, Rodolfo Mattioli, Mara A Cafferata, Roberta Camisa, and Egbert F Smit
    Pemetrexed versus pemetrexed and carboplatin as second-line chemotherapy in advanced non-small-cell lung cancer (NSCLC): results of GOIRC 02-2006 randomized phase II study and pooled analysis with NVALT7 trial.
    J Clin Oncol 30(36): 4501-7, 2012 (IF=17.793)
  • Giorgio Cocconi, Corrado Boni, Maurizio Tonato, Rodolfo Passalacqua, Mariantonietta Colozza, Anna M. Mosconi, Giancarlo Bisagni, Ermanno Rondini, Lina Rodinò, Amalia Carpi, Francesco Di Costanzo, Mauro Brugia, Giuseppe Attardo, Luigi Acito, Riccardo Rossetti, Maria Bella, Roberta Camisa, Francesco Cardinale, Beatrice Dozin.
    Randomized Trial Comparing Cyclophosphamide, Methotrexate, and 5-Fluorouracil (CMF) Regimen with Rotational CMFEV Regimen (E = Epirubicin, V = Vincristine) as Adjuvant Chemotherapy in Moderate Risk Operable Breast Carcinoma.
    Journal of Cancer Therapy 2, 342-353, 2011. (IF=0.14)
  • Emiel Rutgers, Martine J. Piccart-Gebhart, Jan Bogaerts, Suzette Delaloge, Laura Van ‘t Veer, Isabel Teresa Rubio, Giuseppe Viale, Alastair M. Thompson, Rodolfo Passalacqua, Ulrike Nitz, Anita Vindevoghel, Jean-Yves Pierga, Peter M. Ravdin, Gustavo Werutsky, Fatima Cardoso.
    The EORTC 10041/BIG 03-04 MINDACT trial is feasible: Results of the pilot phase
    European Journal of Cancer 47: 2742–2749, 2011